Michael Ryskin is a Managing Director in Equity Research on the Life Science Tools & Diagnostics team. Prior to joining BofA, he was a research scientist at Pfizer in the Oncology Research Unit, where he performed pre-clinical drug discovery. He received a Bachelor’s degree in molecular biology from Cornell University and a Master’s in the same subject from Brown University. He has an MBA from New York University. He is based in New York.